Clinical Trial Update: Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of Taletrectinib for previously treated metastatic CDH1-mutated invasive lobular breast cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Lobular Carcinoma of the Breast

Drugs mentioned

• Taletrectinib (taletrectinib)

Snippet

Sponsor: Megan Kruse, MD | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: SUSPENDED